174 related articles for article (PubMed ID: 22351740)
21. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial.
Arrazubi V; Mata E; Antelo ML; Tarifa A; Herrera J; Zazpe C; Teijeira L; Viudez A; Suárez J; Hernández I; Vera R
Ann Surg Oncol; 2019 Sep; 26(9):2805-2811. PubMed ID: 31209673
[TBL] [Abstract][Full Text] [Related]
23. Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
Soave A; Riethdorf S; Dahlem R; Minner S; Weisbach L; Engel O; Fisch M; Pantel K; Rink M
BJU Int; 2017 Jun; 119(6):854-861. PubMed ID: 28182321
[TBL] [Abstract][Full Text] [Related]
24. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
25. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
26. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy.
Soave A; Riethdorf S; Dahlem R; von Amsberg G; Minner S; Weisbach L; Engel O; Fisch M; Pantel K; Rink M
Int J Cancer; 2017 Jan; 140(2):381-389. PubMed ID: 27668704
[TBL] [Abstract][Full Text] [Related]
27. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study.
Ju M; Kao GD; Steinmetz D; Chandrasekaran S; Keefe SM; Guzzo TJ; Christodouleas JP; Hahn SM; Dorsey JF
Cancer Biol Ther; 2014 Jun; 15(6):683-7. PubMed ID: 24618718
[TBL] [Abstract][Full Text] [Related]
28. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; Ignatiadis M; Lebofsky R; van Laere SJ; Meier-Stiegen F; Sandri MT; Vidal-Martinez J; Politaki E; Consoli F; Bottini A; Diaz-Rubio E; Krell J; Dawson SJ; Raimondi C; Rutten A; Janni W; Munzone E; Carañana V; Agelaki S; Almici C; Dirix L; Solomayer EF; Zorzino L; Johannes H; Reis-Filho JS; Pantel K; Pierga JY; Michiels S
Lancet Oncol; 2014 Apr; 15(4):406-14. PubMed ID: 24636208
[TBL] [Abstract][Full Text] [Related]
29. [Tumor cells in the peripheral blood of patients with urothelial carcinoma of the bladder: detection and impact of circulating].
Rink M; Soave A; Engel O; Fisch M; Riethdorf S; Pantel K
Urologe A; 2014 Apr; 53(4):501-8. PubMed ID: 24671248
[TBL] [Abstract][Full Text] [Related]
30. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
31. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
32. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma.
Blom A; Bhatia S; Pietromonaco S; Koehler K; Iyer JG; Nagase K; Paulson K; Sabath DE; Nghiem P
J Am Acad Dermatol; 2014 Mar; 70(3):449-55. PubMed ID: 24388423
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial.
Nicolazzo C; Busetto GM; Gradilone A; Sperduti I; Del Giudice F; Loreni F; Cortesi E; de Berardinis E; Gazzaniga P; Raimondi C
Oncologist; 2019 May; 24(5):612-616. PubMed ID: 30944184
[TBL] [Abstract][Full Text] [Related]
35. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.
Rink M; Chun FK; Minner S; Friedrich M; Mauermann O; Heinzer H; Huland H; Fisch M; Pantel K; Riethdorf S
BJU Int; 2011 May; 107(10):1668-75. PubMed ID: 20735381
[TBL] [Abstract][Full Text] [Related]
36. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
[TBL] [Abstract][Full Text] [Related]
37. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
40. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
Pernot S; Badoual C; Terme M; Castan F; Cazes A; Bouche O; Bennouna J; Francois E; Ghiringhelli F; De La Fouchardiere C; Samalin E; Bachet JB; Borg C; Ducreux M; Marcheteau E; Stanbury T; Gourgou S; Malka D; Taieb J
Eur J Cancer; 2017 Jul; 79():15-22. PubMed ID: 28456090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
